## SPECIAL TOPIC: Fighting cancer with armed T cells

ISSN: 1674-7305 (Print) 1869-1889 (Online)

1. Editorial

### [Armed T cells with CAR for cancer immunotherapy](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5047-2D0&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=uU3tkjBJrm6vLicjRNqmqC1B8w-1pfo_wY2IJvDgNkU&e=)

[Yu-Quan Wei](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Yu-2DQuan-2BWei-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=6bjj-2Zucu1zerjomOZTWB_uZHAu52jo4IReFngrQVs&e=) Pages 331-332

[**Download PDF**(294KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5047-2D0.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=Ru3842Yj0t3Qj4QB6Wv5nNPjIDvhyEzkYwPeQPYYZ58&e=)

1. Review

### [Establishing guidelines for CAR-T cells: challenges and considerations](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5026-2D5&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=B3ne1ygBPMLwcJ9DP_MNqRUJleFxRNzqUEdqajyCj1I&e=)

[Wei Wang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Wei-2BWang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=gbk5seQT2tnxu3Uou0DHFkskTyUdzKOe8mnKUEyN3yI&e=), [Di-Yuan Qin](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Di-2DYuan-2BQin-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=26ZSlQU56d_jCZI5nSglciTOBNkwZ8V1NSCgXakWH3Y&e=), [Bing-Lan Zhang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Bing-2DLan-2BZhang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=s8kYZWlCNcMwwcyPeSfizE_beDY_VX__fvc0pjRNiB8&e=), [Wei Wei](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Wei-2BWei-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=XHAgjhiWD6Yy6Ndk5BaL2l0292Fzml9KnMdcaMXziO8&e=)…Pages 333-339

[**Download PDF**(911KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5026-2D5.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=hKWb3PvuZbv3fdYLRilkJJpb_nHlnaqDLLotZgtP4KU&e=)

1. Review

### [Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5027-2D4&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=nLywL_eZ3_wzU-_iZKmuW56LZPcFj7rsnD6x9ALzN6k&e=)

[Bing-Lan Zhang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Bing-2DLan-2BZhang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=s8kYZWlCNcMwwcyPeSfizE_beDY_VX__fvc0pjRNiB8&e=), [Di-Yuan Qin](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Di-2DYuan-2BQin-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=26ZSlQU56d_jCZI5nSglciTOBNkwZ8V1NSCgXakWH3Y&e=), [Ze-Ming Mo](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Ze-2DMing-2BMo-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=Y3ZOWyV2MzzjydsOuvDCaGmoGG0XhVdRfe9Pdps7C1k&e=), [Yi Li](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Yi-2BLi-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=1IOa8K8KDJPi4iHviPawpgntzi3z1OFlBkonQZPqiCU&e=), [Wei Wei](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Wei-2BWei-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=XHAgjhiWD6Yy6Ndk5BaL2l0292Fzml9KnMdcaMXziO8&e=)…Pages 340-348

[**Download PDF**(446KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5027-2D4.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=6eg_eSZ9vXjnwrnKZk8u4WQShFe-QWa6pgMq2bJ2h9s&e=)

1. Review

### [Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5034-2D5&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=T7XkOYw7KsNMP0t_63G4x5iji0VAkB8Wmf6_iyuiBCc&e=)

[Can Luo](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Can-2BLuo-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=F5Cm2gD_w5d-w6VRHpk7yEViZcJkwJfhH6S2NI9CXuw&e=), [Jianshu Wei](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Jianshu-2BWei-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=83yGF0rLjJPGYyo-1DPAK_ereNYOOwKX1dtTwtgO4v8&e=), [Weidong Han](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Weidong-2BHan-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=_RZijfePRrS6azrbgISK9AvQ9L4Yd0QJKrVvhZjAPhQ&e=) Pages 349-359

[**Download PDF**(345KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5034-2D5.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=DL8ixSS-G6jImhFxCBs15iQOzEtGKPeVq3EGWCX5PYo&e=)

1. Review

### [Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5025-2D6&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=okpLYbBwjAbR1GC9MZ3zLJbZMxddLzR_zGuNjEldnw0&e=)

[Shengmeng Di](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Shengmeng-2BDi-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=9sAWnAFj9hdxfDl7EL_iR2Cpj1FwnNrV9XMe6kgg9aU&e=), [Zonghai Li](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Zonghai-2BLi-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=pYvNbPEN56aXaLyrc2x2GKSxI9l60PsfqdF-oV3pObo&e=) Pages 360-369

[**Download PDF**(328KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5025-2D6.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=KTo4J1qJQMaKon3jTEP-qwQuHmo2zyRTRrNb3mxJQVs&e=)

1. Review

### [Adoptive therapy with CAR redirected T cells for hematological malignancies](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5036-2D3&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=K8c6T575lx1-2yVCmVxd0Z8YAmR-nq-jj70vgUdudFY&e=)

[Shiqi Li](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Shiqi-2BLi-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=7Xpzk1di7TJWpBRwv8r4gfl7POcSwOK7KmjP3ywwOFk&e=), [Zhi Yang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Zhi-2BYang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=QpbOjqiPg60QhouI5SBNfN-E--Ota-m08EVF4ojXYHY&e=), [Junjie Shen](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Junjie-2BShen-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=ZrEYiuetSy2AXCXUAKzIzoG-Dw5MMM27dK0BdezdF20&e=), [Juanjuan Shan](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Juanjuan-2BShan-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=KINcQa4SvF2vAgQE9hsXAZOI4ciG5YpfslIWXr5pRQY&e=), [Cheng Qian](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Cheng-2BQian-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=VfZMxoKIHr_0td_kByljouBh5jvpi1IgF4Jfbni-P9I&e=) Pages 370-378

[**Download PDF**(308KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5036-2D3.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=My7HG4-mC-xUyzI1Paan_Y5WWETTrXu8CEhhg7cvT-Y&e=)

1. Research Paper

### [An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5035-2D4&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=29QKe_6Dsd-Ams1s9G_Q5IeMAo6I5Y0Knpo0rDtUkKE&e=)

[Yajing Zhang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Yajing-2BZhang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=sgcUPQlR5d1ZXFpQOkzGa1xmyk9Se46GBtrdQFAS1IQ&e=), [Wenying Zhang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Wenying-2BZhang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=ZR2-r_DUb6u2qNckZSSXas1OgDNSEO2nK1047xnITME&e=), [Hanren Dai](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Hanren-2BDai-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=u_zpJaAAomGmefM9O6rygMRXZThU8l_wDPP7z8xlbWw&e=), [Yao Wang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Yao-2BWang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=wqL6yngL5fdF9fl4u3w0h6AS8iX6YSyGi58clu-_7YE&e=)…Pages 379-385

[**Download PDF**(880KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5035-2D4.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=6r3MW_OOcLLDbUd_aK__quUBAlL5TjX44xKk2aOS8-k&e=)

1. Research Paper

### [Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5024-2D7&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=YHqdMH-AKX8yDXc_YwDwd-7lyGbsIK79TD1uHr_Z8ac&e=)

[Fengtao You](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Fengtao-2BYou-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=nU43B_PGj9QpYp9Su1kpTqOYbI-2O_tZCM19RNDqglw&e=), [Licui Jiang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Licui-2BJiang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=rqRgFAXStoFxr4-iJeZfls-DeZ7h2Eer5qL3SHLw9A4&e=), [Bozhen Zhang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Bozhen-2BZhang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=a-ZTda4Ikm2W-sBOQXluUXeZIOScyjporubbab78Bi4&e=), [Qiang Lu](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Qiang-2BLu-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=uQHzPKQyASzD2Z_w01QaO6JF5wCZPL1PKImNKKamyzk&e=), [Qiao Zhou](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Qiao-2BZhou-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=ia04M_iobUD_ClWZ9td9wCvVKk4PM0rpWrPYApW7HV4&e=)…Pages 386-397

[**Download PDF**(2319KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5024-2D7.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=4IG3ZhO9oTMAJt8sIeSqo2I5hxKa-q8uClUX5x4Ub5o&e=)

### [Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_article_10.1007_s11427-2D016-2D5023-2D8&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=8WAgEwz6xgQxl9mhXD1JSRFNuN_pPFOcgAewFG0goho&e=)

[Kaichao Feng](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Kaichao-2BFeng-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=Kc62DeAxXuK2tK7b7jzVIzRgay2FSWWpV4jVJ-CtDfY&e=), [Yelei Guo](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Yelei-2BGuo-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=7nQIOBnWo45qXWOclMBZd9otlehfmkoyvLZEbSQXF5g&e=), [Hanren Dai](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Hanren-2BDai-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=u_zpJaAAomGmefM9O6rygMRXZThU8l_wDPP7z8xlbWw&e=), [Yao Wang](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Yao-2BWang-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=wqL6yngL5fdF9fl4u3w0h6AS8iX6YSyGi58clu-_7YE&e=), [Xiang Li](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_search-3Ffacet-2Dcreator-3D-2522Xiang-2BLi-2522&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=qF-G3SWSe765XS5VfQXffh-UAOhIbxDcxRQ6PS4HDJY&e=)…Pages 468-479

[**Download PDF**(1670KB)](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.springer.com_content_pdf_10.1007-252Fs11427-2D016-2D5023-2D8.pdf&d=DwMFbw&c=ZQs-KZ8oxEw0p81sqgiaRA&r=rOMURTZ4fslq9dKzVxltN4xNU-D2Ru1wiL30akyNmwk&m=wIlFd-tqX4CAcODk7HaIMeMuXK6kg8RUxWZqEp8-1sI&s=L5usliiXfAvOQBZXWNAu5s_qUee7PUzLXANGn_xAFH0&e=)